Table 3.
Safety profile of LABA/LAMA FDCs according to SUCRA analysis
| Treatment | SUCRA value (%) |
|---|---|
| A/F 400/12 | 86.00 |
| T/O 5/5 | 75.67 |
| Placebo | 49.67 |
| U/V 62.5/25 | 47.33 |
| G/F 14.4/9.6 | 39.00 |
| G/I 15.6/27.5 | 37.00 |
| G/I 50/110 | 15.00 |
Abbreviations: A, aclidinium; F, formoterol; FDCs, fixed-dose combinations; G, glycopyrronium; I, indacaterol; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; O, olodaterol; SUCRA, surface under the cumulative ranking curve; T, tiotropium; U, umeclidinium; V, vilanterol.